With the approval of olaparib, how will your treatment of patients with pancreatic cancer change?
How might the use of PARP inhibitors evolve in the treatment of pancreatic cancer? Read this commentary from Dr Philip Philip.
Listen to Philip Agop Philip, MD, PhD, FRCP, and Elena Gabriela Chiorean, MD, discuss the role of testing for biomarkers and the current paradigm of PARP inhibitor therapy in the treatment of pancreatic cancer.
In this downloadable PDF summary from a CCO podcast, Philip Philip, MD, PhD and Elena Chiorean, MD discuss the role of biomarker testing and PARP inhibitors in the treatment of pancreatic cancer.
Listen to Eileen M. O’Reilly, MD, and Naureen Starling, MD, FRCP, discuss emerging therapeutic strategies involving PARP inhibitors that are being investigated for the treatment of pancreatic cancer.
In this downloadable PDF summary from a CCO podcast, Eileen M. O’Reilly, MD, and Naureen Starling, MD, FRCP, compare the role and use of PARP inhibitors in the treatment of pancreatic cancer between the United States and Europe.
In this video roundtable, watch 3 experts give their perspectives on the optimal management of patients with pancreatic cancer using PARP inhibitors, as well as emerging strategies with PARP inhibitors that they find promising.
Download this slideset on the current advances and evolving landscape of PARP inhibitors for patients with pancreatic cancer.
Contact Clinical Care Options
For customer support please email: customersupport@cealliance.com
Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.